Clinical study of [123I] N-(2-diethylaminoethyl)-4-iodobenzamide in the diagnosis of primary and metastatic ocular melanoma.
OBJECTIVE
To assess the value of scintigraphy with [123I]N-(2-diethylaminoethyl)-4-iodobenzamide (BZA), a phase II clinical trial was performed on 48 patients with a suspicion of ocular melanoma.


METHODS
56 examinations were performed to image lesions with a clinical diagnosis of primary ocular melanoma before and/or after treatment, to observe the results in simulating lesions or to image metastases.


RESULTS
Ocular BZA-scintigraphy demonstrated a sensitivity of 86%, and a specificity of 83%. Whole-body scintigraphy was used in the follow-up of treated patients and could be repeated. We imaged orbital recurrence, known and occult metastases, specially in the liver. After 9 conservative treatments ocular BZA-scintigraphy was negative in 9 eyes.


CONCLUSIONS
The BZA-scintigraphy in combination with other diagnostic procedures appeared to be a suitable method in the diagnosis of ocular melanoma and a potentially useful imaging modality to screen for ocular malignant melanoma metastases.
Bacin
F
F
CHU Gabriel Montpied, Service d'Ophtalmologie, Clermont-Ferrand, France.
Michelot
J
J
Bonafous
J
J
Veyre
A
A
Moreau
M F
MF
Kemeny
J L
JL
Chossat
F
F
Bekhechi
D
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D001918:Brachytherapy; D003230:Conjunctival Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D003287:Contrast Media; D015353:Eye Enucleation; D005260:Female; D006801:Humans; D017075:Laser Coagulation; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary / Q000628:therapy; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity; D014604:Uveal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy
D001549:Benzamides; D003287:Contrast Media; C066918:N-(2-(diethylamino)ethyl)-4-iodobenzamide